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Abstract
Background: Delirium is an acute confusional state, common in critical illness and associated with cognitive
decline. There is no effective pharmacotherapy to prevent or treat delirium, although it is scientifically plausible that
thiamine could be effective. Thiamine studies in dementia patients are inconclusive. Aside from small numbers, all
used oral administration: bioavailability of thiamine is poor; parenteral thiamine bypasses this. In the UK, parenteral
thiamine is administered as a compound vitamin B and C solution (Pabrinex®). The aim of this review is to evaluate
the effectiveness of parenteral thiamine (alone or in a compound solution) in preventing or treating delirium in
critical illness.
Methods: We will search for studies in electronic databases (MEDLINE (Pro-Quest), EMBASE, CINAHL, LILACS, CNKI,
AMED, and Cochrane CENTRAL), clinical trials registries (WHO International Clinical Trials Registry, ClinicalTrials.gov,
and Controlled-trials.com), and grey literature (Google Scholar, conference proceedings, and Index to Theses). We
will perform complementary searches of reference lists of included studies, relevant reviews, clinical practice
guidelines, or other pertinent documents (e.g. official documents and government reports). We will consider quasi-
randomised or randomised controlled trials in critically ill adults. We will include studies that evaluate parenteral
thiamine versus standard of care, placebo, or any other non-pharmacological or pharmacological interventions. The
primary outcomes will be the delirium core outcome set, including incidence and severity of delirium and
cognition. Secondary outcomes are adapted from the ventilation core outcome set: duration of mechanical
ventilation, length of stay, and adverse events incidence. Screening, data extraction, and risk of bias assessment will
be undertaken independently by two reviewers. If data permits, we will conduct meta-analyses using a random
effects model and, where appropriate, sensitivity and subgroup analyses to explore sources of heterogeneity.
Discussion: This review will provide evidence for the effectiveness of parental thiamine in the prevention or
treatment of delirium in critical care. Findings will contribute to establishing the need for a multicentre study of
parenteral thiamine in the prevention and treatment of critical care delirium.
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Background
Delirium is an acute confusional state that is common in
critically ill patients and associated with poor clinical
outcomes, including cognitive decline [1]. Patients ex-
periencing delirium require prolonged hospitalisation
and are more likely to require residential or nursing care
at discharge never returning to their own home [1, 2].
The prevalence of delirium is reported to be as much as
74% in critical illness with a high severity of illness and
approximately 50% in patients who require mechanical
ventilation for more than 48 h [3, 4]. There is no
pharmacological treatment known to be effective in the
prevention or treatment in all subtypes of critical care
delirium [5].
Thiamine (vitamin B1) is a water-soluble vitamin and
is essential for aerobic metabolism [6]. After absorption,
thiamine is converted to thiamine monophosphate
(TMP), thiamine diphosphate (TDP), and thiamine tri-
phosphate (TTP) [6]. TDP, also known as thiamine
pyrophosphate (TPP), is the most abundant active form
of thiamine and is an essential co-factor for enzymes in-
volved in carbohydrate metabolism, pyruvate dehydro-
genase, alpha-ketoglutarate dehydrogenase, and
transketolase. It is also important in nerve conduction
[7].
Human stores of thiamine are smaller than other
mammals and deplete with age [8]. Thiamine deficiency
can develop secondary to inadequate nutrition, alcohol
misuse disorders, increased urinary excretion (e.g. di-
uretics), and acute metabolic stress [9]. Patients with
sepsis are frequently thiamine-deficient, and patients
undergoing surgical procedures can also develop
thiamine deficiency [10, 11]. Rates of thiamine deficiency
in critically ill patients range from 10 to 70% depending
on the study design and patient population [10, 12].
Thiamine depletion is especially common in alcohol
abuse and can present as alcohol withdrawal syndrome
(AWS) and Wernicke’s encephalopathy (WE) [13]. Alco-
hol reduces the absorption and subsequent phosphoryl-
ation of thiamine to its active form: thiamine
diphosphate (TDP) [14]. WE is a neurological emergency
resulting from thiamine deficiency with varied neurocog-
nitive manifestations, typically involving mental status
changes, gait, and oculomotor dysfunction [9]. Further-
more, there are now reports that WE can develop in
cancer patients, after poor nutrition and major surgery
(especially gastrointestinal) [10, 15]. WE is notoriously
difficult to diagnose, and delirium has been reported as
an early sign of thiamine depletion in WE [16].
Impaired glucose metabolism has been proposed as a
final common pathway in delirium occurrence [17]. It is
plausible that depletion of TDP contributes to delirium
and later cognitive decline [16]. In delirium and demen-
tia, brain glucose demands increase, and this may not be
met in subgroups presenting with thiamine depletion in
their CNS. Furthermore, TDP, via transketolase, is es-
sential in the synthesis of gamma-aminobutyric acid
(GABA). In the absence of TDP, the excitatory neuro-
transmitter glutamate is formed. Finally, depletion of
TDP has been associated with Alzheimer’s disease in a
number of studies [17–19].
Thiamine, in the oral form, has been studied in de-
mentia, but the findings have been inconclusive, in part
because the numbers were small, and the dose was not
optimised [20, 21]. A Cochrane review of trials (n = 3,
49 patients) to establish the role of thiamine supplemen-
tation in Alzheimer’s disease concluded that studies
were too small and variable to establish whether
thiamine supplementation would confer any benefit [22].
The lack of benefit may be because thiamine is poorly
absorbed enterally [9]. As little as 1.2 mg is actively
transported into the gastrointestinal lumen per 50 mg
dose and potentially less in critical illness [21, 23]. Par-
enteral administration of thiamine overcomes this con-
cern. Furthermore, TDP enters the central nervous
system by an active transport mechanism, and in abun-
dance, after parenteral thiamine, TDP will flood the
brain [9]. Correction of thiamine deficiency and main-
tenance of WBT has the potential of decreasing or pre-
venting delirium in critical illness. In turn, this could
plausibly translate into an improvement of longer-term
cognitive decline [17]. In the UK, parenteral thiamine is
administered in a compound solution (Pabrinex®) of
thiamine, riboflavin, pyridoxine, nicotinamide, and as-
corbic acid [24]. Pabrinex is widely prescribed in alcohol
withdrawal and WE. The adverse effect rate is low re-
ported at 1 in 100,000 or less [24]. This alongside Pabri-
nex’s low cost, approximately £2.50 per infusion,
potentially translates into a safe and cost-effective ther-
apy for delirium.
We are not aware of the use of parenteral thiamine in
any indication out with alcoholism. A systematic review
(SR) of studies will help to uncover relevant research
findings that may support future trials in this area. The
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objective of this study therefore is to evaluate the effect-
iveness of parenteral thiamine (alone or in a compound
solution) in preventing or treating delirium in critically
ill adult patients.
Methods
The protocol is registered on the PROSPERO database
(CRD42019118808) and is reported in accordance with
the reporting guidance provided in the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses
Protocols (PRISMA-P) statement (see checklist in Add-
itional file 1) [25, 26].
Eligibility criteria
Studies will be selected according to the following cri-
teria: study design, participants, interventions and com-
parators, outcomes of interest, and context.
Study design
We will include randomised controlled trials (including
cluster randomised trials) and quasi-randomised trials
defined as trials where participants were allocated to in-
terventions using a method of allocation that is not truly
random. We will exclude retrospective comparative co-
hort studies, case-control or nested case-control studies,
and case series.
Participants
We will include studies of adult patients, aged 16 years
and over, with a planned or unplanned admission to a
critical care or high-dependency facility. The critical care
facility will include cardiac, burns, medical, liver, surgi-
cal, trauma, and mixed critical care facilities. We will
also include studies of patients admitted to areas provid-
ing high-dependency (or level 2) care, that is those re-
quiring more detailed observation or intervention
including support for a single failing organ or postopera-
tive care and those ‘stepping down’ from higher levels of
care. We will exclude studies in neurosurgical critical
care facilities because of the high risk of overlap from
acute brain disorders.
Interventions
We will include studies that evaluate the therapeutic use
of parenteral thiamine in the treatment or prevention of
delirium in critical illness. Parenteral administration
includes intravenous, intramuscular, and subcutaneous
administration. At least one of the outcomes of interest
should be delirium or cognition. The parenteral
thiamine can be administered alone or in a compound
solution including vitamin B complex and Pabrinex®.
There will be no restrictions with regard to the dose, fre-
quency, or duration of administration. We will include
studies in which patients are administered parenteral
thiamine (a) once delirium develops (i.e. treatment), (b)
before delirium develops (i.e. prevention), or (c) before it
is known a patient has delirium (i.e. prevention and
treatment). The intervention should be delivered either
during a critical care or high-dependency admission, on
transfer to a critical care facility, or pre-admission to
critical care. This will include before major surgery with
an expected critical care admission or an emergency ad-
mission with a high-dependency stay.
Comparators
The comparator could be (a) placebo, (b) standard care
management, (c) non-pharmacological intervention (e.g.
cohorting, reduced lighting, restoration of the sleep-
wake cycle, and vocal family communication), and (d) a
pharmacological intervention (e.g. antipsychotic treat-
ment, alpha-2 agonists, melatonin) [27–29]. Thiamine
administered via the gastrointestinal tract either orally,
enterally, or rectal administration will be permitted as
comparators.
Outcome measures
A core outcome set for delirium trials has recently been
established, and we will include the following seven out-
comes [30]:
1. Delirium occurrence (including prevalence or
incidence depending on whether the trial has a
prevention or treatment focus, using a validated
tool as reported by authors)
2. Delirium severity (intensity of delirium symptoms)
3. Time to delirium resolution
4. Health-related quality of life (as reported by
authors)
5. Emotional distress (as reported by authors including
anxiety, depression, acute and post-traumatic stress)
6. Cognition (including memory)
7. Mortality (as reported by authors)
Additionally, we will collect the following relevant sec-
ondary outcomes as they are included in a core outcome
set for critical care ventilation trials and are impacted by
delirium [31]:
1. Duration of mechanical ventilation, including
invasive and/or non-invasive support
2. Length of stay, critical care facility and hospital
3. Incidence and description of all reported adverse
events in intervention groups
Information sources and search strategy
We will search the following electronic databases: Pro-
Quest MEDLINE, EMBASE, CINAHL, Cochrane Central
Registry of Controlled Trials (CENTRAL), AMED,
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LILACS, and CNKI from inception onwards. We will
not apply language restrictions. We will search the refer-
ence lists of included studies for additional studies. We
will search the Cochrane Library, the Database of Ab-
stracts of Reviews of Effects, and the Health Technology
Assessment database for relevant systematic reviews that
included trials missed in the electronic search. We will
also search for unpublished studies and ongoing trials in
the World Health Organization (WHO) International
Clinical Trials Registry (ICTR), ClinicalTrials.gov, and
Controlled-trials.com. If there are studies of interest that
have completed recruitment, we shall contact the princi-
pal investigator and establish whether findings can be in-
cluded. Ongoing studies will be listed in a table of
ongoing studies. We will search grey literature including
Google Scholar, conference proceedings, and Index to
Theses for unpublished trials. A MEDLINE search strat-
egy is available in Additional file 2. We will adapt the
MEDLINE search strategy to other electronic databases.
Screening, selection, and data extraction procedure
Two authors will screen all articles identified from the
search independently. First, titles and abstracts of articles
returned from initial searches will be screened based on
the eligibility criteria outlined above. Second, full texts
will be examined in detail and screened for eligibility.
Third, references of all considered articles will be hand
searched to identify any relevant study missed in the
search strategy. Any disagreement between reviewers
will be resolved by a discussion. After which, they will
independently extract data from included studies using a
standardised data extraction form (Additional file 3). We
will pilot the form on a random sample of five studies
and revise if necessary. Information will be extracted on
study design, setting, participant demographics, details
of the intervention and comparator, study outcomes,
and details of study funding. Disagreements will be dis-
cussed, and if not possible to resolve by consensus, we
will refer to a third reviewer who will act as an arbiter.
Risk of bias assessment
Two authors will independently assess the risk of bias
(ROB) for included studies. For RCTs, we will use the
Cochrane ROB 2.0 tool [32], and for non-randomised
studies (NRS), we will use the ROBINS-I tool [33]. The
effect of interest for both types of assessment will be the
effect of assignment to the intervention (intention to
treat).
Using ROB 2, we will assess the ROB in each included
study in five domains—bias: arising from the randomisa-
tion process, due to deviations from intended interven-
tions, due to missing outcome data, in the measurement
of the outcome, and in the selection of the reported re-
sult. The signalling questions within each domain will be
judged as yes, probably yes, probably no, no, or no infor-
mation, and we will assign a judgement for the domain
as low, some concerns, or high. An overall judgement of
study ROB will be assigned as high (if ROB is high in at
least one domain or some concerns in multiple domains
that lowers confidence), uncertain (if ROB is uncertain
in at least one domain), or low (if ROB is low in all
domains).
Using the ROBINS-I tool, we will assess ROB in NRS
in seven domains—bias: due to confounding, in partici-
pant selection, in the classification of interventions, due
to deviations from intended interventions, due to miss-
ing data, in the measurement outcomes, and in the se-
lection of reported results. The signalling questions
within each domain will be judged as yes, probably yes,
probably no, no, or no information, and we will assign a
judgement for the domain as low, some concerns, or
high and we will assign a judgement for the domain as
low (comparable to an RCT), moderate (good for a NRS,
but not comparable to a RCT), serious (important prob-
lems), critical (very problematic), or no information. An
overall judgement of study ROB will be assigned as low
(low in all domains), moderate (low or moderate in all
domains), serious (serious in at least one domain, but
not critical in any domain), critical (critical in at least
one domain), or no information (lack of information in
at least one or more domains).
We will resolve the disagreement by discussion, and if
necessary, we shall seek the opinion of an independent
arbiter. We will present ROB judgements using the rob-
vis visualisation tool (https://www.riskofbias.info/wel-
come/robvis-visualization-tool). We will use the
assessment of risk of bias to perform sensitivity analyses
based on methodological quality.
Data synthesis and additional analyses
Study characteristics (design, setting, participant demo-
graphics, details of the intervention and comparator, list
of study outcomes, and details of study funding) will be
summarised in a summary of characteristics table.
We will analyse categorical data using the odds ratio
(OR) and 95% confidence interval (CI), and for continu-
ous data, we will calculate mean differences (MD) and
95% CI between treatment groups where outcomes are
measured in the same way. Where outcomes are mea-
sured differently, we will report the data as standardised
mean differences (SMD) and 95% CI. When sufficient
trials are available, we will calculate the pooled estimate
using the random-effects model as it is a more conserva-
tive estimate of treatment effect [34]. We will perform
all quantitative analyses using the RevMan 5.3 software
[35]. For statistically significant reported outcomes, we
will calculate the number needed to treat for a beneficial
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outcome (NNTB) or the numbers needed to treat for
harmful outcome (NNTH).
Individual participants in each trial arm will comprise
the unit of analysis. We anticipate that all trials will have
a parallel group design, and thus, no adjustment will be
necessary for crossover or clustering. We will contact
the corresponding authors of selected trials to provide
missing data.
Clinical heterogeneity (population, type of critical care
facility, delirium assessment tools, and dose and duration
of parenteral thiamine) and methodological heterogen-
eity (risk of bias) will be described and considered in
data synthesis. We will quantify statistical heterogeneity
by estimating the variance between studies using the I2
statistic. The I2 statistic is the proportion of variation in
prevalence estimates that is due to genuine variation in
prevalence rather than sampling (random) error. I2 stat-
istic ranges between 0 and 100% (with values of 0–25%
and 75–100% taken to indicate low and considerable
heterogeneity, respectively). We will also report Tau2
and Cochran Q test with a p value of < 0.05 considered
statistically significant (heterogeneity).
Findings from the core outcome set will be presented
in the ‘summary of findings’ table. One author will con-
duct analyses and report summary statistics when data
are available, similar, and of good quality. If sufficient
studies are available, we will perform a meta-analysis
using Review Manager (RevMan) 5.3. When pooling is
appropriate, we will use a random effects model, which
incorporates variation both within and between studies.
Continuous data for our primary and secondary out-
comes is likely to be skewed. If the skew is considerable
(ratio of the observed mean minus the lowest possible
value divided by the standard deviation (SD) less than
one), we will log transform these data for the primary
analysis by obtaining appropriate data from the corre-
sponding authors of the selected studies or by using the
method described by Higgins and Green [36]. When
pooling is not necessary, we will report findings either in
the text or in summary tables if more appropriate.
Subgroup and sensitivity analysis
If adequate data are available, we will undertake a sub-
group analysis on the following groups for the following
reasons:
1. Participants with reported alcoholism versus not
(thiamine depletion is well reported in those who
abuse alcohol) [9, 37].
2. Delirium prevention versus treatment (to discern
prophylaxis from treatment regimens: prevention
might be administered preoperatively or by
intramuscular injection in the community before
delirium develops [38], whereas treatment therapy
would be administered in critical care after delirium
develops). Prevention and treatment will be the
administration of the intervention in an area where
delirium prevalence is reported as high, for
example, on admission and during stay in the ICU.
We will perform a sensitivity analysis to investigate the
effect on the primary outcome of excluding trials with a
high risk of bias.
Summary of findings tables
We will adopt the Grading of Recommendations, As-
sessment, Development and Evaluations (GRADE) sys-
tem to assess the quality of evidence using within-study
risk of bias (methodological quality), directness of evi-
dence, data heterogeneity, precision of effect estimates,
and risk of publication bias. The quality of evidence will
be assessed in the seven core outcomes (delirium occur-
rence, delirium severity, time to delirium resolution,
health-related quality of life, emotional distress, cogni-
tion, and mortality). We will present the findings using a
‘summary of findings’ (SoF) table constructed in RevMan
5.3.
Meta-biases
We will undertake several strategies to assess bias. We
will determine outcome reporting bias by checking that
outcomes were recorded a priori in the trial protocol
and/or the Clinical Trial Register at the International
Clinical Trials Registry Platform. To check publication
bias, we will construct a funnel plot of the treatment ef-
fect for the primary outcome against trial precision
(standard error) using RevMan 5.3. We will visually in-
spect the funnel plot for asymmetry. If >10 studies are
identified, we will formally test for asymmetry using lin-
ear regression of the intervention effect estimate against
its standard error, weighted by the inverse of the vari-
ance of the intervention effect estimate because of the
continuous nature of our primary outcome variable [39,
40].
Discussion
The pharmacological treatment of delirium and agitation
remains a challenge in acute and critical care. Antipsy-
chotics may have a role in managing the symptoms of
hyperactive and mixed agitation and delirium, but there
is no evidence for their use in the prevention or treat-
ment of hypoactive delirium [5, 41]. Thiamine in the
form of TDP, by reducing oxidative stress, has the po-
tential to become a therapeutic strategy for the preven-
tion and treatment of critical care delirium and even
cognitive decline [18]. Parenteral administration will
overcome the challenge of bioavailability of thiamine
and oral/enteral access in critical illness [9]. The
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formulation of Pabrinex® is widely prescribed in UK crit-
ical care as the source of parenteral thiamine in alcohol-
ism [24].
This proposed review will enable investigators to ana-
lyse existing evidence for parenteral thiamine in treating
and preventing delirium and/or agitation in the critical
care setting. The results will inform the hypotheses,
aims, and objectives for any prospective RCT.
There are limitations to the proposed review at the
study level and at the review level. At the study level,
there may be considerable overlap with the treatment of
alcohol withdrawal syndrome, Wernicke’s encephalop-
athy, and Korsakoff’s psychosis. Moreover, in the UK,
thiamine is administered as Pabrinex, this compound so-
lution contains ascorbic acid, nicotinamide, riboflavin,
and pyridoxine, and in some parts of Europe, parenteral
vitamin B complex is available which contains a number
of B vitamins. Whilst study investigators may believe a
response to delirium should be attributed to thiamine, it
will be impossible to report this absolutely when either
Pabrinex or parenteral vitamin B complex is reported at
the study level. Finally, included studies may have been
conducted at a single site and recruited a low number of
critical care patients.
At the review level, our scoping exercise revealed a
paucity of RCTs, such as occurred in a recent review of
non-pharmacological strategies in critical care delirium
[42]. In that case, the authors included studies in aligned
medical specialties yet were still unable to undertake
meta-analysis due to small numbers. The clinical sce-
nario with parenteral thiamine could well be similar, and
we may be unable to pool data in a meta-analysis, which
could limit the interpretation of findings from the re-
view. Additionally, this review will be limited to the Eng-
lish language which may introduce a risk of publication
bias. In the case that we may need to amend the review
protocol, we will update the protocol in the PROSPERO
database and document this in the full review paper.
We intend to disseminate findings through a number
of mediums. We plan to present the review at an inter-
national critical care conference, submit the review to a
peer-reviewed journal of suitable impact, and dissemin-
ate more broadly through critical care networks on
Twitter and other relevant social media. We anticipate
this review will identify knowledge gaps in research, and
thus, implications for future randomised controlled trials
will be discussed in the final manuscript.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13643-020-01380-z.
Additional file 1. PRISMA-P statement.
Additional file 2. MEDLINE search strategy.
Additional file 3. Data extraction form for delirium and thiamine in the
ICU SR (DELTA-ICU).
Abbreviations
AMED: Allied and Complimentary Medicines Database; AWS: Alcohol
withdrawal syndrome; CAM-ICU: Confusion Assessment Method for the
Intensive Care Unit; CENTRAL: Cochrane Registry of Controlled Trials;
CERQual: Confidence in the Evidence from Reviews of Qualitative research;
CI: Confidence interval; CINAHL: Cumulative Index to Nursing and Allied
Health Literature; CNKI: China Academic Journals Database; DARE: Database
of Abstract of Reviews of Effects; DELTA-ICI: DELirium and ThiAmine in the
Intensive Care Unit; DSM: Diagnostic and Statistical Manual of Mental
Disorders; EMBASE: Excerpta Medica dataBASE; GABA: Gamma-Aminobutyric
acid; GRADE: Grading of Recommendations, Assessment, Development and
Evaluations; ICDSC: Intensive Care Delirium Screening Checklist; ICU: Intensive
care unit; ICTR: International Clinical Trials Registry; IMV: Invasive mechanical
ventilation; LILACS: Latin American and Caribbean Health Science Literature
database; MD: Mean difference; MEDLINE: Medical Literature Analysis and
Retrieval System Online; NEECHAM: Neelon and Champagne Confusion
Scale; NIHR: National Institute for Health Research; NIMV: Non-invasive
mechanical ventilation; NNTB: Number needed to treat for beneficial
outcome; NNTH: Number needed to treat for harmful outcome; NRS: Non-
randomised studies; OR: Odds ratio; RevMan: Review Manager;
RCT: Randomised controlled trial; ROB: Risk of bias; SMD: Standardised mean
difference; SOF: Summary of findings; SR: Systematic review; TDP: Thiamine
diphosphate; TMP: Thiamine monophosphate; TPK: Thiamine
pyrophosphokinase; TPP: Thiamine pyrophosphate; TTP: Thiamine
triphosphate; WBT: Whole blood thiamine; WE: Wernicke’s encephalopathy;
WHO: World Health Organization
Authors’ contributions
All authors contributed equally to the design of the SR protocol and




Availability of data and materials
All data and materials are available on request.





There is no competing interest.
Author details
1Institute of Pharmaceutical Sciences, Kings College London, 150 Stamford
Street, London SE1 9NH, UK. 2Pharmacy Department, Cheyne Wing, Kings
College Hospital, Denmark Hill, London SE5 9RS, UK. 3Wellcome-Wolfson
Institute of Experimental Medicine, Queen’s University Belfast, 97 Lisburn
Road, Belfast, Northern Ireland BT9 7BL, UK. 4Intensive Care Unit, Watford
General Hospital, West Hertfordshire NHS Foundation Trust, Vicarage Road,
Watford, Herts WD18 OHD, UK. 5Faculty of Medicine, Imperial College
London, South Kensington Campus, London SW7 2AZ, UK. 6College of
Medicine and Health, University of Exeter, St Luke’s Campus Heavitree Road,
Exeter EX1 2LU, UK. 7Diabetes and Vascular Medicine, NIHR Clinical Research
Facility, Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK. 8Department
of Critical Care, Kings College London, Guys & St. Thomas’ Hospital, London
SE1 7EH, UK. 9Department of Intensive Care Medicine, Gelre Hospitals,
Apeldoorn PO Box 9014 - 7300, DS, the Netherlands.
McKenzie et al. Systematic Reviews           (2020) 9:131 Page 6 of 8
Received: 26 November 2019 Accepted: 4 May 2020
References
1. Sachdev PS, Blacker D, Blazer DG, Ganguli M, Jeste DV, Paulsen JS, et al.
Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol
[Internet]. 2014;10(11):634–42 Available from: http://www.nature.com/
articles/nrneurol.2014.181.
2. Kennedy M, Enander RA, Tadiri SP, Wolfe RE, Shapiro NI, Marcantonio ER.
Delirium risk prediction, healthcare use and mortality of elderly adults in the
emergency department. J Am Geriatr Soc [Internet]. 2014;62(3):462–9
Available from: http://doi.wiley.com/10.1111/jgs.12692.
3. Pandharipande P, Jackson J, Ely EW. Delirium: acute cognitive dysfunction in
the critically ill. Curr Opin Crit Care [Internet]. 2005;11(4):360–8 Available
from: http://journals.lww.com/00132980-200510000-00003.
4. Mehta S, Cook D, Devlin JW, Skrobik Y, Meade M, Fergusson D, et al.
Prevalence, risk factors, and outcomes of delirium in mechanically ventilated
adults*. Crit Care Med [Internet]. 2015;43(3):557–66 Available from: https://
insights.ovid.com/crossref?an=00003246-201503000-00007.
5. Burry L, Hutton B, Williamson DR, Mehta S, Adhikari NKJ, Cheng W, et al.
Pharmacological interventions for the treatment of delirium in critically ill
adults. Cochrane Database Syst Rev [Internet]. 2019;2019(9) Available from:
http://doi.wiley.com/10.1002/14651858.CD011749.pub2..
6. Lonsdale D. A review of the biochemistry, metabolism and clinical benefits
of thiamin(e) and its derivatives. Evid Based Complement Alternat Med
[Internet]. 2006;3(1):49–59 Available from: http://www.hindawi.com/journals/
ecam/2006/349513/abs/.
7. Woolum JA, Abner EL, Kelly A, Thompson Bastin ML, Morris PE, Flannery AH.
Effect of thiamine administration on lactate clearance and mortality in
patients with septic shock*. Crit Care Med [Internet]. 2018;46(11):1747–52
Available from: http://journals.lww.com/00003246-201811000-00005.
8. Abdou E, Hazell AS. Thiamine deficiency: an update of pathophysiologic
mechanisms and future therapeutic considerations. Neurochem Res
[Internet]. 2015;40(2):353–61 Available from: http://link.springer.com/10.1
007/s11064-014-1430-z.
9. Sechi G, Serra A. Wernicke’s encephalopathy: new clinical settings and
recent advances in diagnosis and management. Lancet Neurol [Internet].
2007 [cited 2020 Jan 29];6(5):442–455. Available from: https://linkinghub.
elsevier.com/retrieve/pii/S1474442207701047.
10. Van Snippenburg W, Reijnders MGJ, Hofhuis JGM, De Vos R, Kamphuis S,
Spronk PE. Thiamine levels during intensive insulin therapy in critically ill
patients. J Intensive Care Med [Internet]. 2017;32(9):559–64 Available from:
https://doi.org/10.1177/0885066616659429.
11. Heming N, Salah A, Meng P, Sivanandamoorthy S, Bounab R, Chevret S,
et al. Thiamine status and lactate concentration in sepsis: a prospective
observational study. Vol. 99, Medicine (United States). Lippincott Williams
and Wilkins; 2020.
12. Collie JTB, Greaves RF, Jones OAH, Lam Q, Eastwood GM, Bellomo R.
Vitamin B1 in critically ill patients: needs and challenges. Clin Chem Lab
Med [Internet]. 2017;55(11):1652–68 Available from: http://www.degruyter.
com/view/j/cclm.2017.55.issue-11/cclm-2017-0054/cclm-2017-0054.xml.
13. Parsons OA, Nixon SJ. Neurobehavioral sequelae of alcoholism. Neurol Clin
[Internet]. 1993 [cited 2020 May 3];11(1):205–218. Available from: https://
linkinghub.elsevier.com/retrieve/pii/S0733861918301786.
14. Day E, Bentham PW, Callaghan R, Kuruvilla T, George S. Thiamine for
prevention and treatment of Wernicke-Korsakoff syndrome in people who
abuse alcohol. Cochrane database Syst Rev [Internet]. 2013;(7):CD004033
Available from: http://doi.wiley.com/10.1002/14651858.CD004033.pub3.
15. Isenberg-Grzeda E, Alici Y, Hatzoglou V, Nelson C, Breitbart W. Nonalcoholic
thiamine-related encephalopathy (Wernicke-Korsakoff syndrome) among
inpatients with cancer: a series of 18 cases. Psychosomatics [Internet]. 2016;
57(1):71–81 Available from: https://linkinghub.elsevier.com/retrieve/pii/
S0033318215001589.
16. Wijnia JW, Oudman E. Biomarkers of delirium as a clue to diagnosis and
pathogenesis of Wernicke−Korsakoff syndrome. Eur J Neurol [Internet]. 2013;
20(12):1531–8 Available from: http://doi.wiley.com/10.1111/ene.12217.
17. Gibson GE, Hirsch JA, Cirio RT, Jordan BD, Fonzetti P, Elder J. Abnormal
thiamine-dependent processes in Alzheimer’s disease. Lessons from
diabetes. Mol Cell Neurosci. 2013;55:17–25.
18. Sang S, Pan X, Chen Z, Zeng F, Pan S, Liu H, et al. Thiamine diphosphate
reduction strongly correlates with brain glucose hypometabolism in
Alzheimer’s disease, whereas amyloid deposition does not. Alzheimers Res
Ther [Internet]. 2018;10(1):26 Available from: https://alzres.biomedcentral.
com/articles/10.1186/s13195-018-0354-2.
19. Pan X, Sang S, Fei G, Jin L, Liu H, Wang Z, et al. Enhanced activities of blood
thiamine diphosphatase and monophosphatase in Alzheimer’s disease.
Potier M-C, editor. PLoS One [Internet]. 2017;12(1):e0167273 Available from:
http://dx.plos.org/10.1371/journal.pone.0167273.
20. Nolan KA, Black RS, Sheu KF, Langberg J, Blass JP. A trial of thiamine in
Alzheimer’s disease. Arch Neurol [Internet]. 1991 [cited 2020 Apr 13];48(1):
81–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1986730.
21. Blass JP. Thiamine and Alzheimer’s disease. Arch Neurol [Internet]. 1988
[cited 2020 Apr 13];45(8):833. Available from: http://archneur.jamanetwork.
com/article.aspx?doi=10.1001/archneur.1988.00520320019008.
22. Rodríguez-Martín JL, Qizilbash N, López-Arrieta JM. Thiamine for Alzheimer’s
disease. Cochrane database Syst Rev [Internet]. 2001;(2):CD001498. Available
from: http://doi.wiley.com/10.1002/14651858.CD001498.
23. Chillistone S, Hardman JG. Factors affecting drug absorption and
distribution. Anaesth Intensive Care Med [Internet]. 2017;18(7):335–9
Available from: https://linkinghub.elsevier.com/retrieve/pii/S1472029917301
054.
24. Pabrinex intravenous high potency, concentrate for solution for infusion -
summary of product characteristics (SmPC) - (eMC) [Internet]. [cited 2019
Jun 13]. Available from: https://www.medicines.org.uk/emc/product/1427/
smpc.
25. Erratum: Preferred Reporting Items for Systematic Review and Meta-Analysis
Protocols (PRISMA-P) 2015: elaboration and explanation (BMJ (2015) 350
(g7647). https://doi.org/10.1136/bmj.g7647. Vol. 354, BMJ (Online). BMJ
Publishing Group; 2016.
26. McKenzie CA, Page VJ, Strain WD, Blackwood B, Ostermann M, Spronk P,
McAuley D. Parenteral thiamine for the prevention and treatment of
delirium in critically ill adults: a systematic review protocol. PROSPERO:
International prospective register of systematic reviews. 2011. https://doi.
org/10.15124/CRD42019118808. Available from: www.crd.york.ac.uk/
CRDWeb/ShowRecord.asp?ID=42019118808.
27. Wan RY, Kasliwal M, McKenzie CA, Barrett NA. Quetiapine in refractory
hyperactive and mixed intensive care delirium: a case series. Crit Care
[Internet]. 2011;15(3):R159 Available from: http://ccforum.biomedcentral.
com/articles/10.1186/cc10294.
28. Cavallazzi R, Saad M, Marik PE. Delirium in the ICU: an overview. Ann
Intensive Care. 2012;2(1):49.
29. Gunther ML, Morandi A, Ely EW. Pathophysiology of delirium in the
intensive care unit. Crit Care Clin [Internet]. 2008 [cited 2020 Jan 23];24(1):
45–65. Available from: https://linkinghub.elsevier.com/retrieve/pii/S07490704
0700084X.
30. Rose L, Page VJ. New core outcomes in delirium for research. http://www.
europeandeliriumassociation.org/uploads/6/1/2/6/61267981/eda_
edinburgh_2019.pdf.
31. Blackwood B, Ringrow S, Clarke M, Marshall JC, Connolly B, Rose L, et al. A
core outcome set for critical care ventilation trials. Crit Care Med [Internet].
2019 [cited 2020 Apr 6];47(10):1324–31. Available from: http://www.ncbi.nlm.
nih.gov/pubmed/31356474.
32. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ,
Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson
A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves
BC, Shepperd S, Shrier I, Stew HJ. RoB 2: a revised Cochrane risk-of-bias tool
for randomized trials. BMJ (in Press) [Internet]. 2019;(July):1–24. Available
from: https://methods.cochrane.org/.
33. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M,
et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of
interventions. BMJ [Internet]. 2016 ;355:i4919. Available from: http://www.
bmj.com/lookup/doi/10.1136/bmj.i4919.
34. Demets DL. Methods for combining randomized clinical trials: strengths and
limitations. Stat Med [Internet]. 1987;6(3):341–50 Available from: http://doi.
wiley.com/10.1002/sim.4780060325.
35. The Cochrane Collaboration. Review Manager (RevMan) [computer
program]. Version 5.3. Copenhagen Nord Cochrane Cent.; 2014.
36. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of
Interventions version 5.1.0 [updated March 2011]. Cochrane Collab. 2011;.
37. Thomson AD, Marshall EJ. The natural history and pathophysiology of
Wernicke’s encephalopathy and Korsakoff’s psychosis. Alcohol Alcohol
[Internet]. 2006 Mar 1;41(2):151–158. Available from: http://academic.oup.
McKenzie et al. Systematic Reviews           (2020) 9:131 Page 7 of 8
com/alcalc/article/41/2/151/134954/THE-NATURAL-HISTORY-AND-
PATHOPHYSIOLOGY-OF.
38. Thomson AD, Cook CCH. Parenteral thiamine and Wernicke’s
encephalopathy: the balance of risks and perception of concern. Alcohol
Alcohol [Internet]. 1997;32(3):207–9 Available from: https://academic.oup.
com/alcalc/article-lookup/doi/10.1093/oxfordjournals.alcalc.a008259.
39. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures.
BMJ [Internet]. 1997 [cited 2019 Jul 21];315(7121):1533–7. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/9432252.
40. Page MJ, Altman DG, McKenzie JE, Shamseer L, Ahmadzai N, Wolfe D, et al.
Flaws in the application and interpretation of statistical analyses in
systematic reviews of therapeutic interventions were common: a cross-
sectional analysis. J Clin Epidemiol [Internet]. 2018;95:7–18 Available from:
https://linkinghub.elsevier.com/retrieve/pii/S0895435617307357.
41. Cavallazzi R, Saad M, Marik PE. Delirium in the ICU: an overview. Ann
Intensive Care [Internet]. 2012;2(1):49 Available from: http://
annalsofintensivecare.springeropen.com/articles/10.1186/2110-5820-2-49.
42. Bannon L, McGaughey J, Verghis R, Clarke M, McAuley DF, Blackwood B. The
effectiveness of non-pharmacological interventions in reducing the
incidence and duration of delirium in critically ill patients: a systematic
review and meta-analysis. Intensive Care Med [Internet]. 2019;45(1):1–12
Available from: http://link.springer.com/10.1007/s00134-018-5452-x.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
McKenzie et al. Systematic Reviews           (2020) 9:131 Page 8 of 8
